Home
Virus
Gene
Disease
Dataset
Download
Help
 
Overview of HIV associated
ID Literature Title Group
1 25174000 A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry.
Mutation
2 30894467 Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
Mutation
3 18177204 Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.
Mutation
4 31735575 Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
Mutation
5 31761656 Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors.
Mutation
6 31920003 Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.
Mutation
7 32179688 Loss of Nef-mediated CD3 down-regulation in the HIV-1 lineage increases viral infectivity and spread.
Mutation
8 32863004 Conformational landscape of non-B variants of HIV-1 protease: A pulsed EPR study.
Mutation
9 32960906 Few amino acid signatures distinguish HIV-1 subtype B pandemic and non-pandemic strains.
Mutation
10 30051611 Flap-site Fragment Restores Back Wild-type Behaviour in Resistant Form of HIV Protease.
Mutation
11 30029500 The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.
Mutation
12 29970102 CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication.
Mutation
13 29792216 HIV-1 Tat phosphorylation on Ser-16 residue modulates HIV-1 transcription.
Mutation
14 29677220 HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G.
Mutation
15 29671808 HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data.
Mutation
16 29666292 Human Immunodeficiency Virus Tat Protein Aids V Region Somatic Hypermutation in Human B Cells.
Mutation
17 28645089 Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Mutation
18 28155724 Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
Mutation
19 28100611 The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block.
Mutation
20 27992544 Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics.
Mutation
21 27267005 Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
Mutation
22 27240358 Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.
Mutation
23 27130466 Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
Mutation
24 26012849 Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Mutation
25 25397483 HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M.
Mutation
26 25393958 Function-based mutation-resistant synthetic signaling device activated by HIV-1 proteolysis.
Mutation
27 25217711 Deletions in the fifth alpha helix of HIV-1 matrix block virus release.
Mutation
28 25212771 Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection.
Mutation
29 24897520 The variable loop 3 in the envelope glycoprotein is critical for the atypical coreceptor usage of an HIV-1 strain.
Mutation
30 24884783 Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.
Mutation
31 24758333 Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Mutation
32 31736889 HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection.
Mutation
33 31548705 Evolution of a reverse transcriptase to map N1-methyladenosine in human messenger RNA.
Mutation
34 31527908 Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
Mutation
35 31511380 Multiple Pathways To Avoid Beta Interferon Sensitivity of HIV-1 by Mutations in Capsid.
Mutation
36 31440231 Role for Gag-CA Interdomain Linker in Primate Lentiviral Replication.
Mutation
37 31409143 Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D↑G↑S mutant in the South African HIV-1 subtype C protease.
Mutation
38 31269034 Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study.
Mutation
39 31266880 Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription.
Mutation
40 31242909 NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal.
Mutation
41 31186327 Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.
Mutation
42 31120420 HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors.
Mutation
43 30327442 Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation.
Mutation
44 30302011 Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan.
Mutation
45 30225969 Fast Magic-Angle Spinning 19 F NMR Spectroscopy of HIV-1 Capsid Protein Assemblies.
Mutation
46 24422669 HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3.
Mutation
47 24418540 Defining HIV-1 Vif residues that interact with CBFβ by site-directed mutagenesis.
Mutation
48 24415937 In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects.
Mutation
49 23011758 HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.
Mutation
50 22651890 Overlapping effector interfaces define the multiple functions of the HIV-1 Nef polyproline helix.
Mutation
51 20494390 Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection.
Mutation
52 17225856 Recruitment and activation of RSK2 by HIV-1 Tat.
Mutation
53 17176473 PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA.
Mutation
54 17140287 HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT.
Mutation
55 17083724 Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription.
Mutation
56 17005036 Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias.
Mutation
57 16970827 Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation.
Mutation
58 16870786 Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.
Mutation
59 16723431 Analysis of HIV-1 replication block due to substitutions at F61 residue of reverse transcriptase reveals additional defects involving the RNase H function.
Mutation
60 16207371 HIV-1 reverse transcriptase mutations that confer decreased in vitro susceptibility to anti-RT DNA aptamer RT1t49 confer cross resistance to other anti-RT aptamers but not to standard RT inhibitors.
Mutation
61 16201018 Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification.
Mutation
62 16054592 L565M mutation in HIV-1 glycoprotein 41 stabilizes the coiled-coil structure.
Mutation
63 15737233 Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription.
Mutation
64 11181702 Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2.
Mutation
65 10620603 The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore.
Mutation
66 32197300 Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors.
Mutation
67 31025011 Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance.
Mutation
68 30918485 The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis.
Mutation
69 30914719 Highly Mutable Linker Regions Regulate HIV-1 Rev Function and Stability.
Mutation
70 30862755 Novel Intersubunit Interaction Critical for HIV-1 Core Assembly Defines a Potentially Targetable Inhibitor Binding Pocket.
Mutation
71 30824746 A Naturally Occurring Polymorphism in the HIV-1 Tat Basic Domain Inhibits Uptake by Bystander Cells and Leads to Reduced Neuroinflammation.
Mutation
72 30814513 Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies.
Mutation
73 30808702 HIV-1 Escape from Small-Molecule Antagonism of Vif.
Mutation
74 30788976 Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors.
Mutation
75 30769947 Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
Mutation
76 30732150 Drug resistance mutations and viral load in human immunodeficiency virus type 2 and dual HIV-1/HIV-2 infected patients in Ghana.
Mutation
77 30709739 An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes.
Mutation
78 30696772 HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry.
Mutation
79 30566493 Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.
Mutation
80 30560871 Characterizing early drug resistance-related events using geometric ensembles from HIV protease dynamics.
Mutation
81 30543749 Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.
Mutation
82 18237398 The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.
Mutation
83 18163907 Design of a trans protease lentiviral packaging system that produces high titer virus.
Mutation
84 18039376 Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages.
Mutation
85 17967060 Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells.
Mutation
86 17910056 Biophysical characterization of Vpu from HIV-1 suggests a channel-pore dualism.
Mutation
87 17676996 Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles.
Mutation
88 17644816 Active site binding and sequence requirements for inhibition of HIV-1 reverse transcriptase by the RT1 family of single-stranded DNA aptamers.
Mutation
89 17559673 HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system.
Mutation
90 17442099 Immunization with HIV protease peptides linked to syngeneic erythrocytes.
Mutation
91 17371591 Mutation in the loop C-terminal to the cyclophilin A binding site of HIV-1 capsid protein disrupts proper virus assembly and infectivity.
Mutation
92 17352531 A look inside HIV resistance through retroviral protease interaction maps.
Mutation
93 17227139 A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Mutation
94 27754450 Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.
Mutation
95 27307565 Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo.
Mutation
96 20010074 N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
Mutation
97 18837996 The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Mutation
98 18808682 Direct Vpr-Vpr interaction in cells monitored by two photon fluorescence correlation spectroscopy and fluorescence lifetime imaging.
Mutation
99 18808097 Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
Mutation
100 18702518 Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Mutation
101 18687142 Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
Mutation
102 18673537 HLA-C increases HIV-1 infectivity and is associated with gp120.
Mutation
103 18638397 Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor.
Mutation
104 18605989 VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability.
Mutation
105 18555885 Tsg101 can replace Nedd4 function in ASV Gag release but not membrane targeting.
Mutation
106 18497858 Proteasomal degradation of TRIM5alpha during retrovirus restriction.
Mutation
107 9874563 The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor.
Mutation
108 32309558 The role of mutations at codons 32, 47, 54, and 90 in HIV-1 protease flap dynamics.
Mutation
109 32235557 Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs.
Mutation
110 32210470 Morphine exposure exacerbates HIV-1 Tat driven changes to neuroinflammatory factors in cultured astrocytes.
Mutation
111 32192810 Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity.
Mutation
112 32111013 Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.
Mutation
113 32001525 Structural basis of second-generation HIV integrase inhibitor action and viral resistance.
Mutation
114 31943114 Binding interface and impact on protease cleavage for an RNA aptamer to HIV-1 reverse transcriptase.
Mutation
115 31941344 The 4th and 112th Residues of Viral Capsid Cooperatively Modulate Capsid-CPSF6 Interactions of HIV-1.
Mutation
116 31885806 HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist.
Mutation
117 31872074 Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance.
Mutation
118 31796053 Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.
Mutation
119 31690677 Analysis of CA Content and CPSF6 Dependence of Early HIV-1 Replication Complexes in SupT1-R5 Cells.
Mutation
120 31640718 Characterization of resistance to a potent D-peptide HIV entry inhibitor.
Mutation
121 27539455 New Antiretroviral Treatment for HIV.
Mutation
122 31370888 The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030.
Mutation
123 31764198 Long-acting implants to treat and prevent HIV infection.
Mutation
124 31767136 Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Mutation
125 31774915 New Perspectives on the Virologic Consequences of M184V or I in Human Immunodeficiency Virus-1 Reverse Transcriptase.
Mutation
126 31776272 HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity.
Mutation
127 31923334 Altered-specificity mutants of the HIV Rev arginine-rich motif-RRE IIB interaction.
Mutation
128 31968566 Sensor Sensibility-HIV-1 and the Innate Immune Response.
Mutation
129 31993580 Following the path: Increasing trends of HIV-1 drug resistance in China.
Mutation
130 32006797 Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mutation
131 32053707 HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral particle.
Mutation
132 32057044 Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.
Mutation
133 32082978 Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Mutation
134 32129987 Defective Strand-Displacement DNA Synthesis Due to Accumulation of Thymidine Analogue Resistance Mutations in HIV-2 Reverse Transcriptase.
Mutation
135 32140396 Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors.
Mutation
136 32143686 Characterization of HIV-1 uncoating in human microglial cell lines.
Mutation
137 32183488 2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication.
Mutation
138 32218488 Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations.
Mutation
139 32266208 In silico Design of Novel HIV-1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4-d]pyrimidines.
Mutation
140 32272714 Recent Advances in HIV-1 Gag Inhibitor Design and Development.
Mutation
141 32295453 A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide.
Mutation
142 32295908 Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.
Mutation
143 32379830 Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Mutation
144 32389483 Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
Mutation
145 32394235 Synthetic strategies, SAR studies, and computer modeling of indole 2 and 3-carboxamides as the strong enzyme inhibitors: a review.
Mutation
146 32403312 Elicitation of Cluster A and Co-Receptor Binding Site Antibodies are Required to Eliminate HIV-1 Infected Cells.
Mutation
147 32411655 An Innovative Sequence-to-Structure-Based Approach to Drug Resistance Interpretation and Prediction: The Use of Molecular Interaction Fields to Detect HIV-1 Protease Binding-Site Dissimilarities.
Mutation
148 32446377 Critical role of PP2A-B56 family protein degradation in HIV-1 Vif mediated G2 cell cycle arrest.
Mutation
149 32462054 Efficient Nonviral Stable Transgenesis Mediated by Retroviral Integrase.
Mutation
150 32470085 Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens.
Mutation
151 32471198 Structural Insights into APOBEC3-Mediated Lentiviral Restriction.
Mutation
152 32478251 Visualizing Tetrahedral Oxyanion Bound in HIV-1 Protease Using Neutrons: Implications for the Catalytic Mechanism and Drug Design.
Mutation
153 32493197 Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Mutation
154 32512519 Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
Mutation
155 32521274 Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity.
Mutation
156 32522853 Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.
Mutation
157 32528834 Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs.
Mutation
158 32538781 HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137.
Mutation
159 32545337 Daxx Inhibits HIV-1 Reverse Transcription and Uncoating in a SUMO-Dependent Manner.
Mutation
160 32553106 MxB sensitivity of HIV-1 is determined by a highly variable and dynamic capsid surface.
Mutation
161 32601157 HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
Mutation
162 32631509 Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7.
Mutation
163 32640577 Targeting HIV-1 RNase H: N'-(2-Hydroxy-benzylidene)-3,4,5-Trihydroxybenzoylhydrazone as Selective Inhibitor Active against NNRTIs-Resistant Variants.
Mutation
164 32643196 Structural investigation of 2-naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site.
Mutation
165 32655148 Impact of Pre-antiretroviral Therapy CD4 Counts on Drug Resistance and Treatment Failure: A Systematic Review.
Mutation
166 32665270 Convergent Evolution of HLA-C Downmodulation in HIV-1 and HIV-2.
Mutation
167 32712537 Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
Mutation
168 32726944 Vpr Is a VIP: HIV Vpr and Infected Macrophages Promote Viral Pathogenesis.
Mutation
169 32727872 In Vitro Quantification of the Effects of IP6 and Other Small Polyanions on Immature HIV-1 Particle Assembly and Core Stability.
Mutation
170 32747359 Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.
Mutation
171 32759675 Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers.
Mutation
172 32778120 Impact of HIV-1 Vpr manipulation of the DNA repair enzyme UNG2 on B lymphocyte class switch recombination.
Mutation
173 32816220 Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
Mutation
174 32824587 Y44A Mutation in the Acidic Domain of HIV-2 Tat Impairs Viral Reverse Transcription and LTR-Transactivation.
Mutation
175 32852081 Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA.
Mutation
176 32858867 HIV-1 Maturation: Lessons Learned from Inhibitors.
Mutation
177 32883642 New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
Mutation
178 32899657 Advances in Continuous Microfluidics-Based Technologies for the Study of HIV Infection.
Mutation
179 32925358 Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
Mutation
180 32960169 Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis.
Mutation
181 32974383 Evidence for Disruption of Mg2+ Pair as a Resistance Mechanism Against HIV-1 Integrase Strand Transfer Inhibitors.
Mutation
182 32974670 In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Mutation
183 32977301 Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
Mutation
184 33041100 DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens.
Mutation
185 33085662 Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease.
Mutation
186 33093566 Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses.
Mutation
187 33096918 Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance.
Mutation
188 33105474 Clinical and Public Health Implications of HIV- Genetic Diversity and Drug Resistance Mutations in Angola: A Systematic Review.
Mutation
189 33126458 Naturally Occurring Calanolides: Occurrence, Biosynthesis, and Pharmacological Properties Including Therapeutic Potential.
Mutation
190 33143469 Scaffold hopping and optimisation of 3',4'-dihydroxyphenyl- containing thienopyrimidinones: synthesis of quinazolinone derivatives as novel allosteric inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H.
Mutation
191 33146906 HIV-1 infection of CD4 T cells impairs antigen-specific B cell function.
Mutation
192 33196554 Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.
Mutation
193 33253162 Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.
Mutation
194 33279288 Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties.
Mutation
195 33314454 A synergy of activity, stability, and inhibitor-interaction of HIV-1 protease mutants evolved under drug-pressure.
Mutation
196 33316353 Conditional activation of an HIV-1 protease attenuated mutant by a leucine zipper dimerization motif.
Mutation
197 33316407 Discovery of novel HIV-1 integrase-LEDGF/p75 allosteric inhibitors based on a pyridine scaffold forming an intramolecular hydrogen bond.
Mutation
198 33332391 Permeability of the HIV-1 capsid to metabolites modulates viral DNA synthesis.
Mutation
199 33374603 Extended Interactions between HIV-1 Viral RNA and tRNALys3 Are Important to Maintain Viral RNA Integrity.
Mutation
200 33390426 A Single Amino Acid Substitution at HIV-1 Protease Termini Dimer Interface Significantly Reduces Viral Particles Processing Efficiency.
Mutation
201 33396460 Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types.
Mutation
202 33425260 The impact of Gag non-cleavage site mutations on HIV-1 viral fitness from integrative modelling and simulations.
Mutation
203 15312229 Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae.
Mutation
204 16790058 Mode of inhibition of HIV-1 Integrase by a C-terminal domain-specific monoclonal antibody.
Mutation
205 16956392 HIV-2 Protease resistance defined in yeast cells.
Mutation
206 17087820 Human TRIM5alpha mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants.
Mutation
207 17134507 Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.
Mutation
208 17509143 Immunogenicity of the outer domain of a HIV-1 clade C gp120.
Mutation
209 17686153 The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment.
Mutation
210 18375964 Analysis of correlated mutations in HIV-1 protease using spectral clustering.
Mutation
211 18445273 14-3-3 theta binding to cell cycle regulatory factors is enhanced by HIV-1 Vpr.
Mutation
212 18498648 Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR.
Mutation
213 18547911 Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
Mutation
214 18597780 Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Mutation
215 19014595 Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication.
Mutation
216 19014951 Defining the DNA substrate binding sites on HIV-1 integrase.
Mutation
217 19300491 Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Mutation
218 21237475 BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action.
Mutation
219 21356539 Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.
Mutation
220 21529874 Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy.
Mutation
221 21569545 Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity.
Mutation
222 22643973 Validation of a novel secretion modification region (SMR) of HIV-1 Nef using cohort sequence analysis and molecular modeling.
Mutation
223 24211331 Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.
Mutation
224 24796579 In silico prediction of mutant HIV-1 proteases cleaving a target sequence.
Mutation
225 25144636 Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.
Mutation
226 25362963 Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
Mutation
227 25383358 Efficient Transduction of LEDGF/p75 Mutant Cells by Gain-of-Function HIV-1 Integrase Mutant Viruses.
Mutation
228 25394027 The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound.
Mutation
229 25499264 The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents.
Mutation
230 25524645 Re-visiting the functional Relevance of the highly conserved Serine 40 Residue within HIV-1 p6(Gag).
Mutation
231 25849367 Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.
Mutation
232 26132818 The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications.
Mutation
233 26537685 Structural Insights into HIV-1 Vif-APOBEC3F Interaction.
Mutation
234 27039930 Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
Mutation
235 27090171 Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.
Mutation
236 27107820 HIV-1 capsid is involved in post-nuclear entry steps.
Mutation
237 27343732 HIV-1 Vpr increases Env expression by preventing Env from endoplasmic reticulum-associated protein degradation (ERAD).
Mutation
238 27355626 Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.
Mutation
239 27992602 Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.
Mutation
240 28153748 A DEAD-Box Helicase Mediates an RNA Structural Transition in the HIV-1 Rev Response Element.
Mutation
241 28302150 Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFβ that is critical for Vif function.
Mutation
242 29222332 Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.
Mutation
243 29763303 Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Mutation
244 30056211 Binding of host factors to stabilized HIV-1 capsid tubes.
Mutation
245 30174310 The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.
Mutation
246 30538178 Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.
Mutation
247 30650070 CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity.
Mutation
248 30717826 HIV-1 Vpu is a potent transcriptional suppressor of NF-κB-elicited antiviral immune responses.
Mutation
249 31126879 Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.
Mutation
250 31172041 Highly Drug-Resistant HIV-1 Protease Mutant PRS17 Shows Enhanced Binding to Substrate Analogues.
Mutation
251 31234536 In Silico Insights into HIV-1 Vpu-Tetherin Interactions and Its Mutational Counterparts.
Mutation
252 31504041 Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies.
Mutation
253 31622432 Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.
Mutation
254 31665623 HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators.
Mutation
255 31906562 HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag.
Mutation
256 31927483 Structure of HIV-2 Nef Reveals Features Distinct from HIV-1 Involved in Immune Regulation.
Mutation
257 31980614 Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements.
Mutation
258 32004936 Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.
Mutation
259 32080249 Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Mutation
260 32098152 Identification of HIV-1 Envelope Mutations that Enhance Entry Using Macaque CD4 and CCR5.
Mutation
261 32180823 Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Mutation
262 32182845 The Determination of HIV-1 RT Mutation Rate, Its Possible Allosteric Effects, and Its Implications on Drug Resistance.
Mutation
263 32187548 Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core.
Mutation
264 32282853 TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner.
Mutation
265 32433992 Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions.
Mutation
266 32605062 Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping.
Mutation
267 32665593 HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains.
Mutation
268 32709741 Absence of cGAS-mediated type I IFN responses in HIV-1-infected T cells.
Mutation
269 32748788 Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens.
Mutation
270 32753492 HIV Vpr Modulates the Host DNA Damage Response at Two Independent Steps to Damage DNA and Repress Double-Strand DNA Break Repair.
Mutation
271 32873191 HIV-1 resists MxB inhibition of viral Rev protein.
Mutation
272 32977702 Identification of Modulators of HIV-1 Proviral Transcription from a Library of FDA-Approved Pharmaceuticals.
Mutation
273 32994325 CPSF6-Dependent Targeting of Speckle-Associated Domains Distinguishes Primate from Nonprimate Lentiviral Integration.
Mutation
274 33095511 Characterization of New DNA Aptamers for Anti-HIV-1 Reverse Transcriptase.
Mutation
275 33096929 How HIV-1 Integrase Associates with Human Mitochondrial Lysyl-tRNA Synthetase.
Mutation
276 33109760 HIV-1 Nef Interacts with LMP7 To Attenuate Immunoproteasome Formation and Major Histocompatibility Complex Class I Antigen Presentation.
Mutation
277 33175558 Multiple Molecular Dynamics Simulations of the Inhibitor GRL-02031 Complex with Wild Type and Mutant HIV-1 Protease Reveal the Binding and Drug-Resistance Mechanism.
Mutation
278 33980829 INI1/SMARCB1 Rpt1 domain mimics TAR RNA in binding to integrase to facilitate HIV-1 replication.
Mutation
279 33979774 Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
Mutation
280 33965042 Near-point-of-care assay with a visual readout for detection of HIV-1 drug resistance mutations: A proof-of-concept study.
Mutation
281 33895602 Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity.
Mutation
282 33883222 Species-specific valid ternary interactions of HIV-1 Env-gp120, CD4, and CCR5 as revealed by an adaptive single-amino acid substitution at the V3 loop tip.
Mutation
283 33863979 CryoET structures of immature HIV Gag reveal six-helix bundle.
Mutation
284 33862046 Variations in Env at amino acids 328 and 330 affect HIV-1 replicative fitness and entry inhibitor sensitivity.
Mutation
285 33836787 A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors.
Mutation
286 33832362 E-pharmacophore based screening to identify potential HIV-1 gp120 and CD4 interaction blockers for wild and mutant types.
Mutation
287 33811831 The SMC5/6 complex compacts and silences unintegrated HIV-1 DNA and is antagonized by Vpr.
Mutation
288 33787846 Synergy and allostery in ligand binding by HIV-1 Nef.
Mutation
289 33785631 Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State.
Mutation
290 33758083 Cytoplasmic CPSF6 Regulates HIV-1 Capsid Trafficking and Infection in a Cyclophilin A-Dependent Manner.
Mutation
291 33754285 1H, 13C and 15N backbone resonance assignment of HIV-1 Gag (276-432) encompassing the C-terminal domain of the capsid protein, the spacer peptide 1 and the nucleocapsid protein.
Mutation
292 33715562 Flavonoids and Acid-Hydrolysis derivatives of Neo-Clerodane diterpenes from Teucrium flavum subsp. glaucum as inhibitors of the HIV-1 reverse transcriptase-associated RNase H function.
Mutation
293 33712691 Cryo-EM structure of the Rous sarcoma virus octameric cleaved synaptic complex intasome.
Mutation
294 33692109 A stable immature lattice packages IP6 for HIV capsid maturation.
Mutation
295 33688632 One-step sequence and structure-guided optimization of HIV-1 envelope gp140.
Mutation
296 33670986 A New Generation of Functional Tagged Proteins for HIV Fluorescence Imaging.
Mutation
297 33669351 Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2.
Mutation
298 33649317 Chemogenetic ON and OFF switches for RNA virus replication.
Mutation
299 33649107 Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
Mutation
300 33648539 HIV-1 Vpr activates host CRL4-DCAF1 E3 ligase to degrade histone deacetylase SIRT7.
Mutation
301 33635925 ZBTB2 represses HIV-1 transcription and is regulated by HIV-1 Vpr and cellular DNA damage responses.
Mutation
302 33572956 Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.
Mutation
303 33571428 Cone-shaped HIV-1 capsids are transported through intact nuclear pores.
Mutation
304 33567378 Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.
Mutation
305 33552873 Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV-1 Env Clustering.
Mutation
306 33537927 Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport.
Mutation
307 33524070 A lysine ring in HIV capsid pores coordinates IP6 to drive mature capsid assembly.
Mutation
308 33515546 Ceramide synthase 2 deletion decreases the infectivity of HIV-1.
Mutation
309 33508465 Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition.
Mutation
310 33503916 Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease.
Mutation
311 33485964 Structural characterization of HIV-1 matrix mutants implicated in envelope incorporation.
Mutation
312 33481784 DEER-PREdict: Software for efficient calculation of spin-labeling EPR and NMR data from conformational ensembles.
Mutation
313 33477685 Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction.
Mutation
314 33466381 Does Antibody Stabilize the Ligand Binding in GP120 of HIV-1 Envelope Protein? Evidence from MD Simulation.
Mutation
Contents
Description
Group Note
  • Mutation Tag: literature about this virus mutation and click the eye icon to see detail mutation information in literature
  • VIS-cistrome Tag: literature associated this virus integration and click the eye icon to see detail information of 3 cistrome factors (histone modification, transcription factor binding site and chromatin accessibility)